Literature DB >> 25462293

Recent insights into the mode of action of memantine and ketamine.

Jon W Johnson1, Nathan G Glasgow2, Nadezhda V Povysheva2.   

Abstract

The clinical benefits of the glutamate receptor antagonists memantine and ketamine have helped sustain optimism that glutamate receptors represent viable targets for development of therapeutic drugs. Both memantine and ketamine antagonize N-methyl-D-aspartate receptors (NMDARs), a glutamate receptor subfamily, by blocking the receptor-associated ion channel. Although many of the basic characteristics of NMDAR inhibition by memantine and ketamine appear similar, their effects on humans and to a lesser extent on rodents are strongly divergent. Some recent research suggests that preferential inhibition by memantine and ketamine of distinct NMDAR subpopulations may contribute to the drugs' differential clinical effects. Here we review studies that shed light on possible explanations for differences between the effects of memantine and ketamine.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25462293      PMCID: PMC4318755          DOI: 10.1016/j.coph.2014.11.006

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  135 in total

Review 1.  A review of the effects of memantine on clinical progression in Alzheimer's disease.

Authors:  David Wilkinson
Journal:  Int J Geriatr Psychiatry       Date:  2011-10-01       Impact factor: 3.485

2.  Probing of NMDA channels with fast blockers.

Authors:  A I Sobolevsky; S G Koshelev; B I Khodorov
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

3.  Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists.

Authors:  Thomas Papouin; Laurent Ladépêche; Jérôme Ruel; Silvia Sacchi; Marilyne Labasque; Marwa Hanini; Laurent Groc; Loredano Pollegioni; Jean-Pierre Mothet; Stéphane H R Oliet
Journal:  Cell       Date:  2012-08-03       Impact factor: 41.582

4.  Distinct functional and pharmacological properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA receptors.

Authors:  Kasper B Hansen; Kevin K Ogden; Hongjie Yuan; Stephen F Traynelis
Journal:  Neuron       Date:  2014-03-05       Impact factor: 17.173

5.  Extrasynaptic NR2B and NR2D subunits of NMDA receptors shape 'superslow' afterburst EPSC in rat hippocampus.

Authors:  Natasha A Lozovaya; Sergei E Grebenyuk; Timur Sh Tsintsadze; Bihua Feng; Daniel T Monaghan; Oleg A Krishtal
Journal:  J Physiol       Date:  2004-05-14       Impact factor: 5.182

6.  Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modelling" of schizophrenia.

Authors:  Gary Gilmour; Elsa Y Pioli; Sophie L Dix; Janice W Smith; Michael W Conway; Wendy T Jones; Sally Loomis; Rebecca Mason; Shahram Shahabi; Mark D Tricklebank
Journal:  Psychopharmacology (Berl)       Date:  2009-05-07       Impact factor: 4.530

7.  A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia.

Authors:  Daniel J Lodge; Margarita M Behrens; Anthony A Grace
Journal:  J Neurosci       Date:  2009-02-25       Impact factor: 6.167

8.  Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings).

Authors:  Georges Mion; Thierry Villevieille
Journal:  CNS Neurosci Ther       Date:  2013-04-10       Impact factor: 5.243

9.  NMDA receptor surface mobility depends on NR2A-2B subunits.

Authors:  Laurent Groc; Martin Heine; Sarah L Cousins; F Anne Stephenson; Brahim Lounis; Laurent Cognet; Daniel Choquet
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-21       Impact factor: 11.205

Review 10.  Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders.

Authors:  Giles E Hardingham; Hilmar Bading
Journal:  Nat Rev Neurosci       Date:  2010-09-15       Impact factor: 34.870

View more
  39 in total

Review 1.  Antidepressant Actions of Ketamine Mediated by the Mechanistic Target of Rapamycin, Nitric Oxide, and Rheb.

Authors:  Maged M Harraz; Solomon H Snyder
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

2.  Hydroxynorketamine Blocks N-Methyl-d-Aspartate Receptor Currents by Binding to Closed Receptors.

Authors:  Jamie A Abbott; Gabriela K Popescu
Journal:  Mol Pharmacol       Date:  2020-06-29       Impact factor: 4.436

3.  Ketamine reduces deleterious consequences of spreading depolarizations.

Authors:  Katelyn M Reinhart; C William Shuttleworth
Journal:  Exp Neurol       Date:  2018-04-10       Impact factor: 5.330

4.  Effects of Mg2+ on recovery of NMDA receptors from inhibition by memantine and ketamine reveal properties of a second site.

Authors:  Nathan G Glasgow; Madeleine R Wilcox; Jon W Johnson
Journal:  Neuropharmacology       Date:  2018-05-12       Impact factor: 5.250

5.  Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis.

Authors:  Neal R Swerdlow; Savita Bhakta; Hsun-Hua Chou; Jo A Talledo; Bryan Balvaneda; Gregory A Light
Journal:  Neuropsychopharmacology       Date:  2015-06-11       Impact factor: 7.853

Review 6.  Targeting Homeostatic Synaptic Plasticity for Treatment of Mood Disorders.

Authors:  Ege T Kavalali; Lisa M Monteggia
Journal:  Neuron       Date:  2020-06-03       Impact factor: 17.173

7.  Memantine and Ketamine Differentially Alter NMDA Receptor Desensitization.

Authors:  Nathan G Glasgow; Nadezhda V Povysheva; Andrea M Azofeifa; Jon W Johnson
Journal:  J Neurosci       Date:  2017-09-06       Impact factor: 6.167

8.  Functional and pharmacological properties of triheteromeric GluN1/2B/2D NMDA receptors.

Authors:  Feng Yi; Subhrajit Bhattacharya; Charles M Thompson; Stephen F Traynelis; Kasper B Hansen
Journal:  J Physiol       Date:  2019-11-02       Impact factor: 5.182

9.  Modulating synaptic NMDA receptors.

Authors:  Kenneth R Tovar; Gary L Westbrook
Journal:  Neuropharmacology       Date:  2016-08-23       Impact factor: 5.250

10.  Pharmacological and Electrophysiological Characterization of Novel NMDA Receptor Antagonists.

Authors:  Rosana Leiva; Matthew B Phillips; Andreea L Turcu; Esther Gratacòs-Batlle; Lara León-García; Francesc X Sureda; David Soto; Jon W Johnson; Santiago Vázquez
Journal:  ACS Chem Neurosci       Date:  2018-06-01       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.